Actionable news
All posts from Actionable news
Actionable news in PFE: PFIZER Inc,

Will Pfizer (PFE) Stock Be Affected by FDA Request for More XELJANZ Data?

NEW YORK (TheStreet) -- Pfizer (PFE - Get Report) received a letter from the Food and Drug Administration saying that the drugmaker needed to provide more safety analyses of the drug Xeljanz, Reuters reports.

Xeljanz is an oral rheumatoid arthritis drug, which was approved in 2012.

Pfizer is currently seeking approval for its supplemental new drug application in which Xeljanz would be used to treat moderate to severe cases of psoriasis, which is a scaly skin condition plaque.

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks with serious upside potential. See them FREE for 14-days.

In response to the FDA letter, the company said, "Pfizer remains committed to Xeljanz based on the strength of the clinical data for the treatment of psoriasis."

Pfizer shares are increasing 3.12% to $34.07 on Thursday afternoon.

Based in New York, Pfizer discovers, develops, manufactures, and sells healthcare products...